334 related articles for article (PubMed ID: 11521719)
1. The basic biology of HER2.
Rubin I; Yarden Y
Ann Oncol; 2001; 12 Suppl 1():S3-8. PubMed ID: 11521719
[TBL] [Abstract][Full Text] [Related]
2. Biology of HER2 and its importance in breast cancer.
Yarden Y
Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
[TBL] [Abstract][Full Text] [Related]
3. The role of overexpressed HER2 in transformation.
Neve RM; Lane HA; Hynes NE
Ann Oncol; 2001; 12 Suppl 1():S9-13. PubMed ID: 11521729
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
5. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
6. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
8. [Tykerb for breast cancer].
Suzuki Y; Saito Y; Okamura T; Tokuda Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):892-5. PubMed ID: 21677477
[TBL] [Abstract][Full Text] [Related]
9. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
[TBL] [Abstract][Full Text] [Related]
10. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.
Pickl M; Ries CH
Oncogene; 2009 Jan; 28(3):461-8. PubMed ID: 18978815
[TBL] [Abstract][Full Text] [Related]
12. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
13. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
14. An overview of HER2.
Lohrisch C; Piccart M
Semin Oncol; 2001 Dec; 28(6 Suppl 18):3-11. PubMed ID: 11774200
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of anti-HER2 monoclonal antibodies.
Baselga J; Albanell J
Ann Oncol; 2001; 12 Suppl 1():S35-41. PubMed ID: 11521720
[TBL] [Abstract][Full Text] [Related]
16. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
Huang Y; Fu P; Fan W
Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
[TBL] [Abstract][Full Text] [Related]
17. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
18. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
19. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
